Back to Video List Back to Home What has been the greatest challenge for you in treating patients with depression during COVID-19? Do you treat patients with depression differently during COVID-19? Any differences in treatment of higher dosing for example? Do you have a specific AD that you think about with respect to patients during this post COVID time? In your experience, do patients with depression present with different symptoms during COVID-19 What about MDD in adolescents and young adults during COVID-19? Do you observe a higher percentage of these patients with disassociative symptoms? We have seen patients who regressed after being in remission and then getting COVID-19 infection, do you believe this is a direct impact of COVID infection? Have you increased the dose of vortioxetine during COVID-19 in patients with depression? Is Brintellix compatible with COVID-19 infection? Do you have any recommendations for the doses of Brintellix for post COVID patients in their 50s-60s could you please explain more about the anti-inflammatory properties of antidepressants, e.g which one has stronger anti-inflammatory effect? Instead of switching, can we add vortioxetine to the first AD treatment to improve emotional blunting or anhedonia? What are the positive effect of vortioxetine on anxiety? Get certificate View other webinars Polling questions before Q&A (3 minutes) Please kindly select True/FaIse to each statement after listening to the webinar Name Email MMC Time is Up!